Gabapentin Capsule
Product Images NDC 82804-294

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 82804-294). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 01)

Chemical structure of gabapentin, depicting a cyclohexane ring attached to an aminomethyl group and acetic acid moiety, consistent with the active ingredient gabapentin.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 02)

A line graph comparing mean pain scores over an 8-week period between placebo and gabapentin 3600 mg/day groups. The x-axis represents weeks from baseline to week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, with gabapentin scores decreasing over time while placebo scores remain relatively steady.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 03)

A line graph depicting mean pain scores over seven weeks, comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks including baseline, and the y-axis represents mean pain score from 0 to 10. The graph is divided into a 3-week dose titration period followed by a 4-week fixed dose period, showing decreasing pain scores for both gabapentin doses compared to placebo.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) dosages across two studies. The y-axis shows percentage responders from 0% to 100%. Study 1 shows 12% for placebo and 29% for GBP 3600. Study 2 shows 14% for placebo, 32% for GBP 1800, and 34% for GBP 2400, with statistical significance indicated for the gabapentin groups.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 05)

A scatter plot chart showing difference percentages against daily doses (mg) for three studies labeled 'STUDY a', 'STUDY b', and 'STUDY c'. The x-axis represents daily dose ranging from 600 mg to 1800 mg, and the y-axis represents difference percentage from 2% to 22%. Data points are marked with squares in three different colors corresponding to each study, annotated with letters 'a', 'b', or 'c'.*

FDA Label Image

82804-294-90 (Image 01)

Gabapentin 400 mg capsules label from Proficient Rx LP, packaging 90 capsules. The label includes the NDC 82804-294-90 and details that each capsule contains 400 mg of gabapentin. Capsules are described as size '0' hard gelatin with an orange opaque cap and body, imprinted with '400 mg' and '234' in blue ink. Manufacturer noted as Graviti Pharmaceuticals Pvt. Ltd., India. Storage instructions and medication guide dispensing advice are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.